Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NANA: NAC in ANOCA
NCT06890507Phase 2Not yet recruiting
- Sponsor
- University of Adelaide
- Start
- Jun 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Angina with non-obstructive coronary arteries (ANOCA) comparing Oral NAC 600mg with Placebo (2 arms). Primary endpoint: Frequency of angina episodes at 8 weeks. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
acetylcysteine
03
Conditions
Angina with non-obstructive coronary arteries (ANOCA)
Beyond the preview
Go deeper on NCT06890507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06890507.